Disturbed tryptophan metabolism in cardiovascular disease

Current Medicinal Chemistry

Volumn 21, Issue 17, 2014, Pages 1931-1937

  Mangge, H ^a,b   Stelzer, I ^a   Reininghaus, E Z ^a   Weghuber, D ^c   Postolache, T T ^d   Fuchs, D ^e  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b BIOTECHMED GRAZ   (Austria)

^c Paracelsus Private Medical School Salzburg   (Austria)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Anemia; Cardiovascular disease; Chronic immune activation syndrome; Mood alteration; Tryptophan breakdown

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 6; LEPTIN; SEROTONIN; TETRAHYDROBIOPTERIN; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE;

ABDOMINAL FAT; ADAPTIVE IMMUNITY; AGING; ANEMIA; BIPOLAR DISORDER; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELLULAR IMMUNITY; CEREBROVASCULAR ACCIDENT; CHRONIC INFLAMMATION; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; ERYTHROID PRECURSOR CELL; GENETIC CODE; GENETIC LINKAGE; HEMOGLOBIN SYNTHESIS; HUMAN; METABOLIC SYNDROME X; MOOD DISORDER; NONHUMAN; OBESITY; OXYGEN SUPPLY; PROTEIN SYNTHESIS; REVIEW; SEPSIS; TH1 CELL; TRYPTOPHAN METABOLISM; ANIMAL; CARDIOVASCULAR SYSTEM; COMPLICATION; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY;

AGING; ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; INFLAMMATION; MOOD DISORDERS; SEPSIS; TRYPTOPHAN;

EID: 84899833118     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140304105526     Document Type: Review

References (77)

1. Schrocksnadel, K.; Wirleitner, B.; Winkler, C.; Fuchs, D. Monitoring tryptophan metabolism in chronic immune activation. Clin. Chim. Acta, 2006, 364(1-2), 82-90.
2. Yoshida, R.; Imanishi, J.; Oku, T.; Kishida, T.; Hayaishi, O. Induction of pulmonary indoleamine 2,3-dioxygenase by interferon. Proc. Natl. Acad. Sci. USA, 1981, 78(1), 129-132.
3. Werner, E.R.; Bitterlich, G.; Fuchs, D.; Hausen, A.; Reibnegger, G.; Szabo, G.; Dierich, M.P.; Wachter, H. Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci., 1987, 41(3), 273-280.
4. Hwu, P.; Du, M.X.; Lapointe, R.; Do, M.; Taylor, M.W.; Young, H.A. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol., 2000, 164(7), 3596-3599.
5. Taylor, M.W.; Feng, G.S. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J., 1991, 5(11), 2516-2522.
6. Byrne, G.I.; Lehmann, L.K.; Kirschbaum, J.G.; Borden, E.C.; Lee, C.M.; Brown, R.R. Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J. Interferon. Res., 1986, 6(4), 389-396.
7. Werner-Felmayer, G.; Werner, E.R.; Fuchs, D.; Hausen, A.; Reibnegger, G.; Wachter, H. Characteristics of interferon induced tryptophan metabolism in human cells in vitro. Biochim. Biophys. Acta, 1989, 1012(2), 140-147.
8. Weiss, G.; Murr, C.; Zoller, H.; Haun, M.; Widner, B.; Ludescher, C.; Fuchs, D. Modulation of neopterin formation and tryptophan degradation by Th1-and Th2-derived cytokines in human monocytic cells. Clin. Exp. Immunol., 1999, 116(3), 435-440.
9. Schroecksnadel, K.; Frick, B.; Winkler, C.; Fuchs, D. Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr. Vasc. Pharmacol., 2006, 4(3), 205-213.
10. Wirleitner, B.; Rudzite, V.; Neurauter, G.; Murr, C.; Kalnins, U.; Erglis, A.; Trusinskis, K.; Fuchs, D. Immune activation and degradation of tryptophan in coronary heart disease. Eur. J. Clin. Invest., 2003, 33(7), 550-554.
11. Fuchs, D.; Moller, A.A.; Reibnegger, G.; Stockle, E.; Werner, E.R.; Wachter, H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J. Acquir. Immune Defic. Syndr., 1990, 3(9), 873-876.
12. Widner, B.; Werner, E.R.; Schennach, H.; Wachter, H.; Fuchs, D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin. Chem., 1997, 43(12), 2424-2426.
13. Murr, C.; Gerlach, D.; Widner, B.; Dierich, M.P.; Fuchs, D. Neopterin production and tryptophan degradation in humans infected by Streptococcus pyogenes. Med. Microbiol. Immunol., 2001, 189(3), 161-163.
14. Pedersen, E.R.; Midttun, O.; Ueland, P.M.; Schartum-Hansen, H.; Seifert, R.; Igland, J.; Nordrehaug, J.E.; Ebbing, M.; Svingen, G.; Bleie, O.; Berge, R.; Nygard, O. Systemic markers of interferongamma-mediated immune activation and long-term prognosis in patients with stable coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 2011, 31(3), 698-704.
15. Brouns, R.; Verkerk, R.; Aerts, T.; De Surgeloose, D.; Wauters, A.; Scharpe, S.; De Deyn, P.P. The role of tryptophan catabolism along the kynurenine pathway in acute ischemic stroke. Neurochem. Res., 2010, 35(9), 1315-1322.
16. Mangge, H.; Summers, K.L.; Meinitzer, A.; Zelzer, S.; Almer, G.; Prassl, R.; Schnedl, W.J.; Reininghaus, E.; Paulmichl, K.; Weghuber, D.; Fuchs, D. Obesity-related dysregulation of the Tryptophan-Kynurenine metabolism: Role of age and parameters of the metabolic syndrome. Obesity (Silver Spring), 2014, 22(1), 195-201.
17. Wang, Y.; Liu, H.; McKenzie, G.; Witting, P.K.; Stasch, J.P.; Hahn, M.; Changsirivathanathamrong, D.; Wu, B.J.; Ball, H.J.; Thomas, S.R.; Kapoor, V.; Celermajer, D.S.; Mellor, A.L.; Keaney, J.F., Jr.; Hunt, N.H.; Stocker, R. Kynurenine is an endotheliumderived relaxing factor produced during inflammation. Nat. Med., 2010, 16(3), 279-285.
18. Darcy, C.J.; Davis, J.S.; Woodberry, T.; McNeil, Y.R.; Stephens, D.P.; Yeo, T.W.; Anstey, N.M. An observational cohort study of the kynurenine to tryptophan ratio in sepsis: association with impaired immune and microvascular function. PLoS One, 2011, 6(6), e21185.
19. Gold, A.B.; Herrmann, N.; Swardfager, W.; Black, S.E.; Aviv, R.I.; Tennen, G.; Kiss, A.; Lanctot, K.L. The relationship between indoleamine 2,3-dioxygenase activity and post-stroke cognitive impairment. J. Neuroinflammation, 2011, 8, 17.
20. Hofmann, F. Ido brings down the pressure in systemic inflammation. Nat. Med., 2010, 16(3), 265-267.
21. Benninghoven, D.; Kaduk, A.; Wiegand, U.; Specht, T.; Kunzendorf, S.; Jantschek, G. Influence of anxiety on the course of heart disease after acute myocardial infarction -risk factor or protective function? Psychother. Psychosom., 2006, 75(1), 56-61.
22. Lewis, S. Broken heart syndrome: perspectives from East and West. Adv. Mind. Body Med., 2005, 21(2), 3-5.
23. Kuehl, L.K.; Penninx, B.W.; Otte, C. [Depression: risk factor for cardiovascular disease]. Nervenarzt, 2012, 83(11), 1379-1384.
24. Goldstein, M.M. Depression-An independent risk factor for cardiovascular disease. JAAPA, 2006, 19(9), 40-42, 44, 46.
25. Patel, A. Review: the role of inflammation in depression. Psychiatr. Danub., 2013, 25 Suppl 2, S216-S223.
26. Langan, C.; McDonald, C. Neurobiological trait abnormalities in bipolar disorder. Mol. Psychiatry., 2009, 14(9), 833-846.
27. Wium-Andersen, M.K.; Orsted, D.D.; Nielsen, S.F.; Nordestgaard, B.G. Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals. JAMA Psychiatr., 2013, 70(2), 176-184.
28. Haroon, E.; Raison, C.L.; Miller, A.H. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology, 2012, 37(1), 137-162.
29. Baune, B.T.; Eyre, H. Anti-inflammatory effects of antidepressant and atypical antipsychotic medication for the treatment of major depression and comorbid arthritis: a case report. J. Med. Case Rep., 2010, 4, 6.
30. Alikhan, S.M.; Lee, J.A.; Dratcu, L. Mirtazapine treatment of a severe depressive episode and resolution of elevated inflammatory markers. Case Rep. Psychiatr., 2013, 2013, 697872.
31. Kupfer, D.J. The increasing medical burden in bipolar disorder. JAMA, 2005, 293(20), 2528-2530.
32. McIntyre, R.S. Overview of managing medical comorbidities in patients with severe mental illness. J. Clin. Psychiatr., 2009, 70(6), e17.
33. McIntyre, R.S.; Soczynska, J.K.; Beyer, J.L.; Woldeyohannes, H.O.; Law, C.W.; Miranda, A.; Konarski, J.Z.; Kennedy, S.H. Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. Curr. Opin. Psychiatr., 2007, 20(4), 406-416.
34. Goldstein, B.I.; Liu, S.M.; Schaffer, A.; Sala, R.; Blanco, C. Obesity and the three-year longitudinal course of bipolar disorder. Bipolar Disord., 2013, 15(3), 284-293.
35. Myint, A.M.; Bondy, B.; Baghai, T.C.; Eser, D.; Nothdurfter, C.; Schule, C.; Zill, P.; Muller, N.; Rupprecht, R.; Schwarz, M.J. Tryptophan metabolism and immunogenetics in major depression: a role for interferon-gamma gene. Brain Behav. Immun., 2013, 31, 128-133.
36. Myint, A.M.; Kim, Y.K. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatr., 2014, 48, 304-313.
37. Rosenblat, J.D.; Cha, D.S.; Mansur, R.B.; McIntyre, R.S. Inflamed moods: A review of the interactions between inflammation and mood disorders. Prog. Neuropsychopharmacol. Biol. Psychiatr., 2014.
38. Reininghaus, E.Z.; McIntyre, R.S.; Reininghaus, B.; Geisler, S.; Bengesser, S.A.; Lackner, N.; Hecht, K.; Birner, A.; Kattnig, F.; Unterweger, R.; Kapfhammer, H.P.; Zelzer, S.; Fuchs, D.; Mangge, H. Tryptophan breakdown is increased in euthymic overweight individuals with bipolar disorder: a preliminary report. Bipolar Disord., 2013. [Epub Ahead of Print].
39. Breunis, M.N.; Kupka, R.W.; Nolen, W.A.; Suppes, T.; Denicoff, K.D.; Leverich, G.S.; Post, R.M.; Drexhage, H.A. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol. Psychiatr., 2003, 53(2), 157-165.
40. Myint, A.M. Kynurenines: from the perspective of major psychiatric disorders. FEBS J., 2012, 279(8), 1375-1385.
41. Berk, M.; Kapczinski, F.; Andreazza, A.C.; Dean, O.M.; Giorlando, F.; Maes, M.; Yucel, M.; Gama, C.S.; Dodd, S.; Dean, B.; Magalhaes, P.V.; Amminger, P.; McGorry, P.; Malhi, G.S. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev., 2011, 35(3), 804-817.
42. Wirleitner, B.; Neurauter, G.; Schrocksnadel, K.; Frick, B.; Fuchs, D. Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr. Med. Chem., 2003, 10(16), 1581-1591.
43. Carney, R.M.; Blumenthal, J.A.; Freedland, K.E.; Stein, P.K.; Howells, W.B.; Berkman, L.F.; Watkins, L.L.; Czajkowski, S.M.; Hayano, J.; Domitrovich, P.P.; Jaffe, A.S. Low heart rate variability and the effect of depression on post-myocardial infarction mortality. Arch. Intern. Med., 2005, 165(13), 1486-1491.
44. Duivis, H.E.; de Jonge, P.; Penninx, B.W.; Na, B.Y.; Cohen, B.E.; Whooley, M.A. Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. Am. J. Psychiatr., 2011, 168(9), 913-920.
45. Elderon, L.; Whooley, M.A. Depression and cardiovascular disease. Prog. Cardiovasc. Dis., 2013, 55(6), 511-523.
46. House, J.S. Social isolation kills, but how and why? Psychosom. Med., 2001, 63(2), 273-274.
47. Robles, T.F.; Kiecolt-Glaser, J.K. The physiology of marriage: pathways to health. Physiol. Behav., 2003, 79(3), 409-416.
48. Reiter, R.J. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev., 1991, 12(2), 151-180.
49. Sakotnik, A.; Liebmann, P.M.; Stoschitzky, K.; Lercher, P.; Schauenstein, K.; Klein, W.; Eber, B. Decreased melatonin synthesis in patients with coronary artery disease. Eur. Heart J., 1999, 20(18), 1314-1317.
50. Altun, A.; Yaprak, M.; Aktoz, M.; Vardar, A.; Betul, U.A.; Ozbay, G. Impaired nocturnal synthesis of melatonin in patients with cardiac syndrome X. Neurosci. Lett., 2002, 327(2), 143-145.
51. Yaprak, M.; Altun, A.; Vardar, A.; Aktoz, M.; Ciftci, S.; Ozbay, G. Decreased nocturnal synthesis of melatonin in patients with coronary artery disease. Int. J. Cardiol., 2003, 89(1), 103-107.
52. Weissbluth, L.; Weissbluth, M. Sudden infant death syndrome: a genetically determined impaired maturation of the photoneuroendocrine system. A unifying hypothesis. J. Theor. Biol., 1994, 167(1), 13-25.
53. Doi, M.; Takahashi, Y.; Komatsu, R.; Yamazaki, F.; Yamada, H.; Haraguchi, S.; Emoto, N.; Okuno, Y.; Tsujimoto, G.; Kanematsu, A.; Ogawa, O.; Todo, T.; Tsutsui, K.; van der Horst, G.T.; Okamura, H. Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat. Med., 2010, 16(1), 67-74.
54. Dominguez-Rodriguez, A.; Abreu-Gonzalez, P.; Sanchez-Sanchez, J.J.; Kaski, J.C.; Reiter, R.J. Melatonin and circadian biology in human cardiovascular disease. J. Pineal. Res., 2010, 49(1), 14-22.
55. Kozirog, M.; Poliwczak, A.R.; Duchnowicz, P.; Koter-Michalak, M.; Sikora, J.; Broncel, M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J. Pineal. Res., 2011, 50(3), 261-266.
56. Muller-Wieland, D.; Behnke, B.; Koopmann, K.; Krone, W. Melatonin inhibits LDL receptor activity and cholesterol synthesis in freshly isolated human mononuclear leukocytes. Biochem. Biophys. Res. Commun., 1994, 203(1), 416-421.
57. Kelly, M.R.; Loo, G. Melatonin inhibits oxidative modification of human low-density lipoprotein. J. Pineal. Res., 1997, 22(4), 203-209.
58. Dominguez-Rodriguez, A.; Abreu-Gonzalez, P.; Garcia-Gonzalez, M.; Ferrer-Hita, J.; Vargas, M.; Reiter, R.J. Elevated levels of oxidized low-density lipoprotein and impaired nocturnal synthesis of melatonin in patients with myocardial infarction. Atherosclerosis, 2005, 180(1), 101-105.
59. Kawashima, K.; Miwa, Y.; Fujimoto, K.; Oohata, H.; Nishino, H.; Koike, H. Antihypertensive action of melatonin in the spontaneously hypertensive rat. Clin. Exp. Hypertens. A., 1987, 9(7), 1121-1131.
60. Cagnacci, A.; Soldani, R.; Yen, S.S. Melatonin enhances cortisol levels in aged women: reversible by estrogens. J. Pineal. Res., 1997, 22(2), 81-85.
61. Fuchs, D.; Hausen, A.; Reibnegger, G.; Werner, E.R.; Werner-Felmayer, G.; Dierich, M.P.; Wachter, H. Immune activation and the anaemia associated with chronic inflammatory disorders. Eur. J. Haematol., 1991, 46(2), 65-70.
62. Weiss, G.; Schroecksnadel, K.; Mattle, V.; Winkler, C.; Konwalinka, G.; Fuchs, D. Possible role of cytokine-induced tryptophan degradation in anaemia of inflammation. Eur. J. Haematol., 2004, 72(2), 130-134.
63. Leshem-Rubinow, E.; Steinvil, A.; Rogowski, O.; Zeltser, D.; Berliner, S.; Weitzman, D.; Raz, R.; Chodick, G.; Shalev, V. Hemoglobin nonrecovery following acute myocardial infarction is a biomarker of poor outcome: A retrospective database study. Int. J. Cardiol., 2013, 169(5), 349-353.
64. Capuron, L.; Schroecksnadel, S.; Feart, C.; Aubert, A.; Higueret, D.; Barberger-Gateau, P.; Laye, S.; Fuchs, D. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol. Psychiatr., 2011, 70(2), 175-182.
65. Pertovaara, M.; Raitala, A.; Lehtimaki, T.; Karhunen, P.J.; Oja, S.S.; Jylha, M.; Hervonen, A.; Hurme, M. Indoleamine 2,3-dioxygenase activity in nonagenarians is markedly increased and predicts mortality. Mech. Ageing Dev., 2006, 127(5), 497-499.
66. Solichova, D.; Melichar, B.; Blaha, V.; Klejna, M.; Vavrova, J.; Palicka, V.; Zadak, Z. Biochemical profile and survival in nonagenarians. Clin. Biochem., 2001, 34(7), 563-569.
67. Palmer, D.B. The Effect of Age on Thymic Function. Front. Immunol., 2013, 4, 316.
68. Pertovaara, M.; Raitala, A.; Juonala, M.; Lehtimaki, T.; Huhtala, H.; Oja, S.S.; Jokinen, E.; Viikari, J.S.; Raitakari, O.T.; Hurme, M. Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study. Clin. Exp. Immunol., 2007, 148(1), 106-111.
69. Raitala, A.; Pertovaara, M.; Karjalainen, J.; Oja, S.S.; Hurme, M. Association of interferon-gamma +874(T/A) single nucleotide polymorphism with the rate of tryptophan catabolism in healthy individuals. Scand. J. Immunol., 2005, 61(4), 387-390.
70. Munn, D.H.; Zhou, M.; Attwood, J.T.; Bondarev, I.; Conway, S.J.; Marshall, B.; Brown, C.; Mellor, A.L. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science, 1998, 281(5380), 1191-1193.
71. Schroecksnadel, K.; Winkler, C.; Wirleitner, B.; Schennach, H.; Fuchs, D. Aspirin down-regulates tryptophan degradation in stimulated human peripheral blood mononuclear cells in vitro. Clin. Exp. Immunol., 2005, 140(1), 41-45.
72. Neurauter, G.; Wirleitner, B.; Laich, A.; Schennach, H.; Weiss, G.; Fuchs, D. Atorvastatin suppresses interferon-gamma -induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines. Clin. Exp. Immunol., 2003, 131(2), 264-267.
73. Schroecksnadel, S.; Sucher, R.; Kurz, K.; Fuchs, D.; Brandacher, G. Influence of immunosuppressive agents on tryptophan degradation and neopterin production in human peripheral blood mononuclear cells. Transpl. Immunol., 2011, 25(2-3), 119-123.
74. Jenny, M.; Klieber, M.; Zaknun, D.; Schroecksnadel, S.; Kurz, K.; Ledochowski, M.; Schennach, H.; Fuchs, D. In vitro testing for anti-inflammatory properties of compounds employing peripheral blood mononuclear cells freshly isolated from healthy donors. Inflamm. Res., 2011, 60(2), 127-135.
75. Tengattini, S.; Reiter, R.J.; Tan, D.X.; Terron, M.P.; Rodella, L.F.; Rezzani, R. Cardiovascular diseases: protective effects of melatonin. J. Pineal. Res., 2008, 44(1), 16-25.
76. Ait-Oufella, H.; Taleb, S.; Mallat, Z.; Tedgui, A. Cytokine network and T cell immunity in atherosclerosis. Semin. Immunopathol., 2009, 31(1), 23-33.
77. Stelzer, I.; Zelzer, S.; Raggam, R.B.; Pruller, F.; Truschnig-Wilders, M.; Meinitzer, A.; Schnedl, W.J.; Horejsi, R.; Moller, R.; Weghuber, D.; Reeves, G.; Postolache, T.T.; Mangge, H. Link between leptin and interleukin-6 levels in the initial phase of obesity related inflammation. Transl. Res., 2012, 159(2), 118-124.